The Human Microbiome Market is segmented on the basis of application, disease, product, and region. Also, the human microbiome research spending market is broadly segmented by product and technology.
Factors such as increased focus on human microbiome therapy, growing demand for human microbiomes as new validated targets for drug development, and the need for early disease detection and diagnosis are expected to drive the growth of the human microbiome market.
On the basis of disease, the human microbiome market comprises of obesity, diabetes, autoimmune disorders, acute diarrhea, cancer, mental disorders, and other diseases. In 2022, the acute diarrhea segment is expected to account for the largest share and is estimated to grow at the highest CAGR during the forecast period (2022–2025).
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904
On the basis of product, the human microbiome research spending market is characterized into instruments and consumables. The instruments segment is further divided into laboratory instruments and analyzers, while, the consumables segment is further bifurcated into kits and reagents. The consumables segment is estimated to grow at the highest CAGR during the forecast period (2016–2021) owing to the repeated purchases of consumables as compared to instruments.
Enterome Bioscience (France), Yakult (Japan), DuPont (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome Inc. (U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences (U.S.), Osel, Inc. (U.S.), and Merck (U.S.) are the major players in the human microbiome market. Domination of the individual segments in this market will depend on the core competencies of different players.
Companies that launch products targeted at specific indications in the human microbiome market are likely to maintain their positions in this market. Pfizer is one such company; it releases medicines and vaccines for specific indications. The firm also entered into an agreement with Second Genome for microbiome research in obesity and metabolic disorders.
Companies in the human microbiome market are majorly focusing on expanding and entering segments for new indications and technology. The key strategy is to expand market share through acquisitions and connect financially with firms having common values and goals. To gain maximum market share, companies have been aggressively signing agreements, collaborations, and partnerships with third-party vendors. Enterome Bioscience is one such company the company focuses on developing biomarkers, companion diagnostic kits, and therapeutic solutions.
The company provides products and technologies in the emerging areas of disease management for human gut microbiome and drugs for the treatment of various microbiome-related diseases, such as inflammatory bowel disease, metabolic diseases, and related disorders.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
